Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Healthcare Reports | Infertility - Optimizing a market bounded by social opinion and physician preference

Infertility - Optimizing a market bounded by social opinion and physician preference

"IntroductionThe market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.ScopeAnalysis of patient potential, unmet needs, market dynamics, and clinical trial design in infertility, supported by opinion leader comment Assessment of pipeline drugs and future treatment trends and their impact on prescribing patterns and behavior Patient based and sales based market forecasts to 2016, the latter providing a breakdown by region, drug class, marketed brands and pipeline drugs Coverage of emerging infertility markets which, in light of reproductive tourism, may offer revenue growth potentialHighlightsKey differentiators will permit Organon's Org-36286 (corifollitropin alpha) and Merck Serono's Pergoveris (r-FSH and r-LH), to cannibalize some share from their proprietors' franchise leading therapies. However, these agents do not appear to satisfy unmet need and this will prevent sales from rivaling Puregon and Menopur (hMG). The lack of education of non-specialist physicians limits the number of women receiving treatment. It should be a primary goal of the market to make these doctors more knowledgeable and to implement incentives to encourage patient referral. New opportunities exist in the development of products to support embryological techniques; cryopreservation, microarrays and in vitro maturation. These procedures will expand the treatable patient population as all women with the intention of preserving and protecting embryos will be eligible for treatment, not just those that are infertile.Reasons to PurchaseQuantify the future size of the infertility market and the number of women eligible for infertility treatment to 2016 in the US, 5EU, and Japan Understand unmet needs and opportunities in the infertility market based on key opinion leader comments Benchmark key late-stage infertility compounds against current market leading brands"

10-Oct-07 Format: PDF & DataPack Pages: 189
Table fo Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions